Skip to content

Making regenerative medicine a part of everyday medicine

Cook MyoSite is leading the pursuit of muscle-derived cell therapies to solve unmet needs in mainstream indications

MYO_BkGd_Data_Periwinkle_&_RobinEgg_grad 2
Rectangle 116

Our story is a human story

Cook MyoSite, Inc., a subsidiary of the Cook Group, was established in 2002 to pioneer advancements in cellular technologies. Driven by a belief in the human body's restorative abilities, Cook MyoSite leverages extensive expertise in muscle-derived cell technology for therapeutic applications. 

Our commitment to innovation, quality, and scientific exploration has propelled the development and delivery of autologous muscle-derived cell (AMDC) technologies, now under investigation in leading clinical trials for various medical uses. We partner with researchers and companies across the globe, offering insights, products, and services to support research in human muscle cell applications. For more than 20 years, our team has been dedicated to overcoming scientific boundaries, championing the body's healing capabilities, and enabling individuals to harness their own muscles for recovery.

Rectangle 116
MYO_BkGd_Data_Periwinkle_&_RobinEgg_grad 2
top-center
Cook-Myosite---2024-275 Mobile

Our story is a human story

Cook MyoSite, Inc., a subsidiary of the Cook Group, was established in 2002 to pioneer advancements in cellular technologies. Driven by a belief in the human body's restorative abilities, Cook MyoSite leverages extensive expertise in muscle-derived cell technology for therapeutic applications. 

Our commitment to innovation, quality, and scientific exploration has propelled the development and delivery of autologous muscle-derived cell (AMDC) technologies, now under investigation in leading clinical trials for various medical uses. We partner with researchers and companies across the globe, offering insights, products, and services to support research in human muscle cell applications. For more than 20 years, our team has been dedicated to overcoming scientific boundaries, championing the body's healing capabilities, and enabling individuals to harness their own muscles for recovery.

Cook-Myosite---2024-275

Our Leaders

MYO_BkGd_Data_Periwinkle_&_RobinEgg_grad 1
Carl Cook, MBA
CEO, Cook Group; President, Cook MyoSite, Inc.

Carl Cook earned his bachelor’s degree in electrical engineering from Purdue University and his MBA from the University of Iowa. Carl joined Cook Group in 1988, founded by his father, Bill Cook. Si...

Ron Jankowski, PhD
Vice President, Regulatory and Scientific Affairs

Ron Jankowski has been with Cook MyoSite since its founding and has more than 20 years of experience in translational medical and biologic product development. He earned his bachelor’s degree in ch...

Ryan Pruchnic, MS, MBA
Managing Vice President

Ryan Pruchnic earned his bachelor’s degree in biology and his master’s degree in exercise physiology from the University of Pittsburgh and his MBA from the Joseph M. Katz Graduate School of Busines...

Our Journey

2002

Cook MyoSite is formed.

2004

First Phase I/II Female Stress Urinary Incontinence (SUI) clinical trial begins.

2007

Cook MyoSite business expands and the headquarter building, 105 Delta Drive, opens.

2013

Phase I/II Fecal Incontinence clinical trial begins. Cook MyoSite expands clinical investigations with a trial examining the use of a person’s own cells on fecal incontinence caused by anal sphincter weakness.

2017

As clinical trials expand, Cook MyoSite opens a new facility across the street at 100 Delta Drive. The company begins producing cell products for two physician-sponsored studies investigating AMDC technology:

• Phase I/II study for underactive bladder

• Phase I/II study for tongue dysphagia

2020

Phase I/II underactive bladder clinical trial is completed. The FDA grants the RMAT designation to iltamiocel for the female stress urinary incontinence indication, and recruitment begins for the second Phase III study, known as the CELLEBRATE study. 

2022

The FDA grants a second RMAT designation for iltamiocel, this time for the fecal incontinence indication. 

2024

The first participant in Cook MyoSite's fecal incontinence trial, known as DigniFI, receives an iltamiocel injection. The FDA grants a third RMAT designation to iltamiocel, this time for the oropharyngeal dysphagia indication. 

2025

Enrollment for the Phase III CELLEBRATE study concludes. 
Cook Myosite - 2024-16-1
CAREERS

Discover what’s Humanly Possible at Cook MyoSite

Cook MyoSite is at the forefront of groundbreaking advancements in the medical field, venturing into uncharted territories of scientific discovery and technological innovation. At the core of our philosophy lies a profound belief in the vast, untapped potential within our groundbreaking technologies and within the human body itself.

We hold an unwavering belief that every individual who joins our organization has the potential to conceive and develop revolutionary ideas capable of reshaping the world as we know it. It is precisely this conviction that has driven us to cultivate a diverse workplace powered by an entrepreneurial spirit where each team member is genuinely valued and recognized for the integral role they play in advancing our mission.

Our small company tackles big challenges, aiming to unlock the potential in our technologies and the human body. If you're ready to push the boundaries of what's humanly possible, join us.